NewGenIvf Group (NIVF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the F-1/A for FY2025, filed Sep 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NIVF SEC filings page.
NewGenIvf Group Limited (NIVF) reported $4.7M in revenue for fiscal year 2025, down 13.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business has a shrinking gross-profit base, while reported earnings are not converting into cash despite a much larger balance sheet.
FY2025 reported net income of$9.9M sat beside operating cash flow of-$10.9M , so accounting profit did not fund day-to-day operations. Financing inflows of$19.0M and investing outflows of$7.6M instead dominated cash movement, helping explain why the balance sheet expanded while operations consumed cash.
Revenue fell
Assets expanded
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of NewGenIvf Group Limited's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
NewGenIvf Group Limited's reported operating margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 8/100.
NewGenIvf Group Limited's revenue declined 13.0% year-over-year, from $5.4M to $4.7M. This contraction results in a growth score of 18/100.
NewGenIvf Group Limited carries a low D/E ratio of 0.15, meaning only $0.15 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.12, NewGenIvf Group Limited holds $3.12 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 79/100.
NewGenIvf Group Limited's reported free cash flow margin for fiscal year 2025 is below the lowest share of revenue this page publishes, so the figure is not shown here. This dimension scores 2/100.
NewGenIvf Group Limited generates a 37.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 5/100.
NewGenIvf Group Limited scores -0.28, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $10.7M against total assets of $32.7M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
NewGenIvf Group Limited passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, NewGenIvf Group Limited used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
NewGenIvf Group Limited reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
NewGenIvf Group Limited generated $4.7M in revenue in fiscal year 2025. This represents a decrease of 13.0% from the prior year.
NewGenIvf Group Limited's EBITDA was -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
NewGenIvf Group Limited reported $9.9M in net income in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
NewGenIvf Group Limited earned $27.36 per diluted share (EPS) in fiscal year 2025.
Cash & Balance Sheet
NewGenIvf Group Limited recorded an outflow of $11.1M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
NewGenIvf Group Limited held $759K in cash against $4.1M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
NewGenIvf Group Limited's gross margin was 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 13.4 percentage points from the prior year.
NewGenIvf Group Limited's ROE was 37.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
NewGenIvf Group Limited invested $135K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 154.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
NIVF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25F-1/A | FY24F-1/A | FY23F-1/A | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Revenue | $4.7M-13.0% | $5.4M+5.8% | $5.1M-13.6% | $5.9M+44.3% | $4.1M |
| Cost of Revenue | $3.8M+4.6% | $3.6M+4.4% | $3.5M-21.6% | $4.4M+42.4% | $3.1M |
| Gross Profit | $956K-47.7% | $1.8M+8.6% | $1.7M+9.4% | $1.5M+50.1% | $1.0M |
| SG&A Expenses | $11.7M+291.1% | $3.0M+82.2% | $1.6M+43.9% | $1.1M+37.9% | $826K |
| Operating Income | -$10.7Mn/m | -$1.2M-2847.3% | $42K-89.4% | $399K+100.6% | $199K |
| EBITDA | -$10.5Mn/m | -$1.1M-1654.2% | $73K-85.3% | $499K+36.6% | $365K |
| Interest Expense | $616K-20.8% | $779K+1586.2% | $46K | N/A | N/A |
| Income Tax | N/A | -$487K | N/A | $208K-29.4% | $295K |
| Net Income | $9.9Mn/m | -$525K-503.0% | $130K-71.6% | $459Kn/m | -$533 |
| EPS (Basic) | $1932.59 | -$39678.88 | $117173.70 | $4.72 | $0.00 |
| EPS (Diluted) | $27.36 | -$39678.88 | $117173.70 | $4.72 | $0.00 |
| Diluted Shares (Avg) | 361,113 | 13 | 1 | 28,797 | 560,000 |
Not reported in any period shown, so not listed: R&D Expenses.
NIVF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25F-1/A | FY24F-1/A | FY23F-1/A | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Total Assets | $32.7M+814.6% | $3.6M-20.3% | $4.5M+54.5% | $2.9M | N/A |
| Current Assets | $7.4M+132.7% | $3.2M+29.0% | $2.5M+2.5% | $2.4M | N/A |
| Cash & Equivalents | $759K+65.7% | $458K+746.0% | $54K+96.3% | $28K-4.2% | $29K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Inventory | $335K+315.0% | $81K-36.0% | $126K+169.2% | $47K | N/A |
| Accounts Receivable | $167K+238.2% | $49K+425.3% | $9K-27.9% | $13K | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0 |
| Total Liabilities | $6.7M+33.1% | $5.1M+307.6% | $1.2M-55.7% | $2.8M | N/A |
| Current Liabilities | $2.4M-13.0% | $2.7M+142.4% | $1.1M-56.1% | $2.6M | N/A |
| Non-Current Liabilities | $4.4M+86.8% | $2.3M+1866.0% | $119K-52.1% | $249K | N/A |
| Long-Term Debt | $4.1M+75.9% | $2.3M | N/A | N/A | N/A |
| Total Equity | $26.6Mn/m | -$1.0M-128.1% | $3.7M+563.4% | $563K | N/A |
| Retained Earnings | $8.9Mn/m | -$986Kn/m | -$461Kn/m | -$592K | N/A |
Not reported in any period shown, so not listed: Goodwill.
NIVF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25F-1/A | FY24F-1/A | FY23F-1/A | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Operating Cash Flow | -$10.9Mn/m | -$8.3Mn/m | -$1.8M-203.2% | $1.7M+19.4% | $1.4M |
| Depreciation & Amortization | $188K+864.6% | $20K-37.4% | $31K-69.0% | $101K-39.7% | $167K |
| Stock-Based Compensation | N/A | N/A | N/A | $240K+20.0% | $200K |
| Capital Expenditures | $135K+154.5% | $53K-24.1% | $70K-26.0% | $94K+469.8% | $17K |
| Free Cash Flow | -$11.1Mn/m | -$8.3Mn/m | -$1.8M-213.6% | $1.6M+14.1% | $1.4M |
| Investing Cash Flow | -$7.6Mn/m | -$53Kn/m | -$70Kn/m | -$94Kn/m | -$17K |
| Financing Cash Flow | $19.0M+118.9% | $8.7M+361.1% | $1.9Mn/m | -$1.6Mn/m | -$1.5M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
NIVF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25F-1/A | FY24F-1/A | FY23F-1/A | FY2220-F | FY2120-F |
|---|---|---|---|---|---|
| Gross Margin | 20.2%-13.4pp | 33.6%+0.9pp | 32.7%+6.9pp | 25.9%+1.0pp | 24.9% |
| Operating Margin | -226.9% | -21.4%-22.2pp | 0.8%-5.9pp | 6.7%+1.9pp | 4.8% |
| Net Margin | 209.0% | -9.7%-12.2pp | 2.5%-5.2pp | 7.7%+7.7pp | 0.0% |
| Return on Equity | 37.1% | N/A | 3.5%-78.0pp | 81.5% | N/A |
| Return on Assets | 30.2%+44.9pp | -14.7%-17.6pp | 2.9%-12.9pp | 15.8% | N/A |
| Current Ratio | 3.12+2.0x | 1.17-1.0x | 2.19+1.3x | 0.94 | N/A |
| Debt-to-Equity | 0.15 | N/A | N/A | N/A | N/A |
| Liabilities-to-Equity | 0.25 | N/A | 0.33-4.6x | 4.98 | N/A |
| Asset Turnover | 0.14-1.4x | 1.52+0.4x | 1.14-0.9x | 2.05 | N/A |
| FCF Margin | -234.0% | -153.1% | -35.8%-62.9pp | 27.2%-7.2pp | 34.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| NewGenIvf Group Limited NIVF | FY2025 | $4.7M | $9.9M | N/A | $990K | 32/100 |
| Concord Medical Services Holding Limited CCM | FY2025 | $65.9M | -$13.3M | -20.2% | $17.6M | 45/100 |
| American Shared Hospital Services AMS | FY2025 | $28.1M | -$1.6M | -5.5% | $8.4M | 37/100 |
| Cryo-Cell International Inc. CCEL | FY2025 | $31.6M | -$2.4M | -7.7% | $35.9M | 26/100 |
| Basel Medical Group Ltd BMGL | FY2025 | $8.9M | -$8.4M | -94.0% | $7.0M | 21/100 |
Where NewGenIvf Group Limited Ranks
Frequently Asked Questions
What is NewGenIvf Group Limited's annual revenue?
NewGenIvf Group Limited (NIVF) reported $4.7M in total revenue for fiscal year 2025. This represents a -13.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewGenIvf Group Limited's revenue growing?
NewGenIvf Group Limited (NIVF) revenue declined by 13.0% year-over-year, from $5.4M to $4.7M in fiscal year 2025.
Is NewGenIvf Group Limited profitable?
Yes, NewGenIvf Group Limited (NIVF) reported a net income of $9.9M in fiscal year 2025.
What is NewGenIvf Group Limited's EBITDA?
NewGenIvf Group Limited (NIVF) had EBITDA of -$10.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does NewGenIvf Group Limited have?
As of fiscal year 2025, NewGenIvf Group Limited (NIVF) had $759K in cash and equivalents against $4.1M in long-term debt.
What is NewGenIvf Group Limited's gross margin?
NewGenIvf Group Limited (NIVF) had a gross margin of 20.2% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is NewGenIvf Group Limited's return on equity (ROE)?
NewGenIvf Group Limited (NIVF) has a return on equity of 37.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NewGenIvf Group Limited's free cash flow?
NewGenIvf Group Limited (NIVF) recorded an outflow of $11.1M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewGenIvf Group Limited's operating cash flow?
NewGenIvf Group Limited (NIVF) recorded an outflow of $10.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are NewGenIvf Group Limited's total assets?
NewGenIvf Group Limited (NIVF) had $32.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are NewGenIvf Group Limited's capital expenditures?
NewGenIvf Group Limited (NIVF) invested $135K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is NewGenIvf Group Limited's current ratio?
NewGenIvf Group Limited (NIVF) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.
What is NewGenIvf Group Limited's debt-to-equity ratio?
NewGenIvf Group Limited (NIVF) had a debt-to-equity ratio of 0.15 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is NewGenIvf Group Limited's liabilities-to-equity ratio?
NewGenIvf Group Limited (NIVF) had a liabilities-to-equity ratio of 0.25 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is NewGenIvf Group Limited's return on assets (ROA)?
NewGenIvf Group Limited (NIVF) had a return on assets of 30.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NewGenIvf Group Limited's P/E ratio?
NewGenIvf Group Limited (NIVF) trades at 0.1x earnings, its market capitalization divided by $9.9M net income, FY2025. The market capitalization is $990K as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is NewGenIvf Group Limited's price-to-sales ratio?
NewGenIvf Group Limited (NIVF) trades at 0.2x sales, its market capitalization divided by $4.7M revenue, FY2025. The market capitalization is $990K as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does NewGenIvf Group Limited's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, NewGenIvf Group Limited (NIVF) held $759K in cash, cash equivalents and investments, and reported an operating cash outflow of $10.9M over that year. Dividing the one by the other, the reported balance equals about 1 month of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is NewGenIvf Group Limited's Altman Z-Score?
NewGenIvf Group Limited (NIVF) has an Altman Z-Score of -0.28, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NewGenIvf Group Limited's Piotroski F-Score?
NewGenIvf Group Limited (NIVF) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewGenIvf Group Limited's earnings high quality?
For every $1 of reported earnings, NewGenIvf Group Limited (NIVF) used $1.11 of operating cash (-$10.9M OCF vs $9.9M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can NewGenIvf Group Limited cover its interest payments?
NewGenIvf Group Limited (NIVF) reported an operating loss of $10.7M against $616K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is NewGenIvf Group Limited?
NewGenIvf Group Limited (NIVF) scores 32 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.